patients with ulcerative colitis had high risk of colitic cancer. A:patients suspected dysplasia(low/high grade) or cancer. B:patients had plan of treatment of the dysplasia or cancer.
Conditions
Interventions
40mL AIM solution (0.6% acetic acid with 0.4% IC) was sprinkled onto the lesions and images were recorded.
Sponsors
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with ulcerative colitis(UC) in clinical remission. 2.Patients visits within a year. 3.Patients who have underwent colonoscopy as UC surveillance. 4.Patients with UC in remission (Mayo score <2) 5.Patients had dysplasia or/and cancer. 6.Patient age is 20 years of age 7.Patients with informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with a history that has received the surgical operation of UC. 2.Pregnant patients. 3.Patients who are breast-feeding. 4.Patients who have been the administration of the other study drug or investigational drugs within three months before the start of the administration of the study drug. 5.Patients has determined that inappropriate by principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of detected colitic cancer or dysplasia, comparison using white light between using AIM. | — |
Countries
Japan
Contacts
Public ContactYuusakuSugihara
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Gastroenterology and Hepatology
Outcome results
None listed